Novavax NanoFlu achieved all primary endpoints in phase 3 clinical trial

, , , , ,

On Mar. 24, 2020, Novavax announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant, in adults aged 65 and older.

Using the U.S. Food and Drug Administration (FDA) criteria for accelerated approval of seasonal influenza vaccines, the trial evaluated the immunogenicity and safety of NanoFlu compared to Fluzone Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine.

Tags:


Source: Novavax
Credit: